ORIGINAL ARTICLE
Ahead of Print

Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer


1 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Correspondence Address:
Bo Dai,
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032
China
Ding-Wei Ye,
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aja.aja_39_21

PMID: 34100390

The purpose of our study is to investigate the prognostic value of phosphatase and tensin homolog on chromosome 10 (PTEN) expression in patients with de novo metastatic castration naïve prostate cancer (mCNPC). A total of 205 patients with mCNPC at Fudan University Shanghai Cancer Center (Shanghai, China) were retrospectively examined. Immunohistochemical staining of PTEN was performed on prostate biopsy samples of these patients. Associations among clinicopathological features, patient survival and PTEN protein expression were analyzed. PTEN loss occurred in 58 of 205 (28.3%) patients. Loss of PTEN was significantly correlated with high metastatic volume (P = 0.017). No association between PTEN expression and Gleason score was observed. Patients with PTEN loss had significantly shorter progression-free survival (PFS, P < 0.001) and overall survival (OS, P < 0.001) compared with patients with intact PTEN expression. Multivariate analysis showed that elevated alkaline phosphatase, high metastatic volume and PTEN loss were independent poor prognostic factors for PFS. The Eastern Cooperative Oncology Group performance status (ECOG PS) 2 and PTEN loss were independent poor prognostic factors for OS. The adjusted hazard ratio of PTEN loss for PFS and OS was 1.67 (95% confidence interval [CI]: 1.14–2.43, P = 0.008) and 1.95 (95% CI: 1.23–3.10, P = 0.005), respectively. PTEN loss was also significantly associated with shorter PFS (P = 0.025) and OS (P < 0.001) in patients with low-volume metastatic disease. Our data showed that PTEN loss is an independent predictor for shorter PFS and OS in patients with de novo mCNPC.


[FULL TEXT] [PDF]
Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Zhang JY
    -  Kong YY
    -  Wang QF
    -  Yang YJ
    -  Liu Z
    -  Lin N
    -  Ye DW
    -  Dai B
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1046    
    PDF Downloaded70    
    Cited by others 1    

Recommend this journal